Safety and activity of radium-223 in metastatic castration-resistant prostate cancer: the experience of Istituto Nazionale dei Tumori.
CONCLUSIONS: Our study provides clinically useful real-world data on radium-223, highlighting the importance of multidisciplinary patient management to guarantee the best continuum of care for patients with mCRPC.
PMID: 32116138 [PubMed - as supplied by publisher]
Source: Tumori - Category: Cancer & Oncology Tags: Tumori Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | Clinical Trials | Pain | Pain Management | Prostate Cancer | Study